Advertisement
UK markets open in 4 hours 11 minutes

  • NIKKEI 225

    37,770.40
    +141.92 (+0.38%)
     

  • HANG SENG

    17,526.02
    +241.48 (+1.40%)
     

  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     

  • GOLD FUTURES

    2,345.90
    +3.40 (+0.15%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,541.04
    +159.49 (+0.31%)
     

  • CMC Crypto 200

    1,390.48
    +7.90 (+0.57%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

GSK aims to file up to 20 new drugs for approval by 2020

Reuters - UK Focus

LONDON, Nov 3 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Tuesday it had the potential to file up to 20 new drugs for approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair.

Britain's biggest drugmaker is trying to boost low investor expectations for its product pipeline by hosting its first research and development day in more than a decade.

The company highlighted advanced and early-stage projects in respiratory medicine, immunology, oncology, vaccines, HIV and other infections, and rare diseases.

(Reporting by Ben Hirschler; Editing by Keith Weir)